Under the restrictive terms of the BAT agreement, annual royalties to 22nd Century were capped at $25 million per year. Now that the agreement has been terminated, the Company is free to engage in licensing agreements and strategic partnerships with any and all tobacco companies – with no restrictions, limits, or “caps” on licensing royalties. This development is especially significant in light of the announcement made...by the United States Food and Drug Administration...
Can you answer why the federal govt. uses XXII's IP for its studies?
Market Data 
Markets 
AI
